Receptor and other drug targets pharmacogenetics Flashcards

1
Q

What are the main targets for drug action?

A

Receptors, Enzymes, Ion channels, Transporters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is typically affected by polymorphisms related to receptors?

A

Function of receptor or level of expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the basic structure of G-coupled protein receptors?

A

7 transmembrane proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which region is important in coupling to G-proteins in G-coupled protein receptors?

A

Linker region between transmembrane domains 5 and 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Is it usually possible to study phenotype in receptor gene polymorphisms like in CYP genes?

A

No, it’s not usually possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What methods are used to discover polymorphisms in receptor genes?

A

Scanning of genes by sequencing or other appropriate methods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are common approaches to study receptor polymorphisms?

A
  • Coding sequence studies
  • Upstream polymorphism studies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which receptors are important drug targets related to adrenoreceptors?

A

Beta 1 and Beta 2 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the product of the B2-adrenegic receptor gene?

A

ADRB2 gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How many known polymorphisms are in the coding region of the B2-adrenegic receptor?

A

9 known polymorphisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the first coding region polymorphism identified in the B2-adrenegic receptor?

A

Arg16Gly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What effect does the Arg16Gly polymorphism have on agonist binding?

A

Gly16 variant enhances down-regulation compared to Arg16

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the effect of the Arg16 form of ADRB2 on short-acting beta agonists?

A

Associated with increased agonist induced down-regulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Did studies show a difference in response to long-acting beta agonists based on codon 16 genotype?

A

No, studies failed to show any difference

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the significance of the polymorphism at amino acid 16 in B2 adrenergic receptor?

A

It is the ligand binding site, outside the cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What haplotypes are associated with B2 adrenergic receptor?

A
  • Ca (Caucasian)
  • A (African American)
  • As (Asian)
  • H-L (Hispanic-Latino)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What was the outcome of the study by Connie et al, 2000 regarding B2AR?

A

Identified 13 SNPs in a continuous region of B2AR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the main types of adrenoreceptors in the heart?

A

B1 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the common polymorphism in the ADRB1 gene?

20
Q

What is the frequency of the Gly and Arg variants in the ADRB1 gene?

A
  • Glycine variant: 0.26
  • Arginine variant: 0.74
21
Q

What is the target enzyme for coumarin anticoagulants including warfarin?

A

Vitamin-K epoxide reductase (VKOR)

22
Q

What is the gene that encodes VKOR?

23
Q

What percentage of inter-individual variation in coumarin anticoagulant dose do VKORC1 and CYP2C9 account for?

24
Q

What are the two polymorphisms identified in VKORC1?

A
  • G-1639A
  • C1173T
25
Q

What does the presence of the G-1639A polymorphism indicate about VKORC1 expression?

A

Lower VKORC1 expression

26
Q

What is the common cause of warfarin resistance?

A

Mutations in the coding region of VKORC1

27
Q

What is the role of HMG-CoA reductase?

A

Converts HMG-CoA into mevalonic acid, the rate limiting step for cholesterol biosynthesis

28
Q

What is the effect of polymorphisms in the HMGCR gene?

A

Associated with decreased response to statin treatment

29
Q

What defect is present in cystic fibrosis patients?

A

Defect in the CFTR gene which codes for an ion channel

30
Q

What drug targets the G551D gating defect in cystic fibrosis?

31
Q

What was the improvement in lung function after 48 weeks of Ivacaftor treatment?

A

Improved by 11%

32
Q

What percentage of cases is D involved in?

A

Approx. 5% of cases only

33
Q

What is the gating defect in the context of D?

A

The channel no longer responds to the ligand

34
Q

What drug targets the G551D gating defect?

35
Q

What effect does Ivacaftor have on sweat chloride levels after 48 weeks?

A

Significantly reduced

36
Q

By what percentage did lung function (FEV1.0) improve after Ivacaftor treatment?

37
Q

What is the percentage decrease in pulmonary exacerbations observed with Ivacaftor?

A

55% decrease

38
Q

What is the cost of Ivacaftor per patient per year?

39
Q

For which patients is Ivacaftor approved by the EMA?

A

Patients over 6 years old with G551D or R117H allele

40
Q

What did a patient quote about the effectiveness of Ivacaftor?

A

‘It’s like someone else’s lungs are inside of me’

41
Q

What is the target mutation of the drug Orkambi?

A

Common F508del mutation

42
Q

What two components make up Orkambi?

A

Ivacaftor plus lumacaftor

43
Q

What does lumacaftor help with in Orkambi?

A

Movement of CFTR to plasma membrane

44
Q

What is the newest drug that targets F508del more efficiently than Orkambi?

45
Q

What components does Symkevi consist of?

A

Ivacaftor, tezacaftor, and elexacaftor